ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV

NCT00901524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatitis

Interventions

DRUG: Peg-interféron alpha 2a + ribavirin

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]